Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER-positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor

被引：3
|
作者：
Karimi, Leena [1 ]
Alves, Carla L. [1 ]
Terp, Mikkel G. [1 ]
Tuttolomondo, Martina [1 ]
Portman, Neil [2 ,3 ]
Ehmsen, Sidse [1 ,4 ]
Johansen, Lene E. [1 ]
Bak, Martin [5 ]
Lim, Elgene [2 ,3 ]
Ditzel, Henrik J. [1 ,6 ,7 ]
机构：
[1] Univ Southern Denmark, Inst Mol Med, Dept Canc & Inflammat Res, Odense, Denmark
[2] Garvan Inst Med Res, Sydney, NSW, Australia
[3] Univ New South Wales Sydney, Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia
[4] Odense Univ Hosp, Inst Clin Res, Dept Oncol, Odense, Denmark
[5] Sydvestjysk Sygehus, Dept Pathol, Esbjerg, Denmark
[6] Odense Univ Hosp, Acad Geriatr Canc Res AgeCare, Odense, Denmark
[7] Univ Southern Denmark, Inst Mol Med, Dept Canc & Inflammat Res, DK-5000 Odense, Denmark
来源：
CANCER COMMUNICATIONS | 2023年 / 43卷 / 06期
关键词：
PLUS FULVESTRANT; MONARCH; 2; ABEMACICLIB; ALPELISIB;
D O I：
10.1002/cac2.12425
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：720 / 725
页数：6
相关论文
共 50 条
  • [1] Triple combination targeting ER, CDK4/6, and PI3K inhibits tumor growth in ER plus breast cancer resistant to combined fulvestrant and CDK4/6 or PI3K inhibitor.
    Karimi, Leena
    Alves, Carla L.
    Terp, Mikkel G.
    Tuttolomondo, Martina
    Ditzel, Henrik J.
    CANCER RESEARCH, 2021, 81 (13)
  • [2] In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER plus breast cancer
    O'Brien, Neil A.
    Tomaso, Emmanuelle D.
    Ayala, Raul
    Tong, Luo
    Issakhanian, Shawnt
    Linnartz, Ronald
    Finn, Richard S.
    Hirawat, Samit
    Slamon, Dennis J.
    CANCER RESEARCH, 2014, 74 (19)
  • [3] Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review
    Husna, Siti Muhamad Nur
    Tan, Hern-Tze Tina
    Mohamud, Rohimah
    Dyhl-Polk, Anne
    Wong, Kah Keng
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [4] CDK4/6 BLOCKADE IMPROVES THE EFFICACY OF PI3K INHIBITION IN BREAST CANCER
    不详
    CANCER DISCOVERY, 2014, 4 (09) : 983 - 983
  • [5] Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer
    Lee, Cha Len
    Cremona, Mattia
    Farrelly, Angela
    Workman, Julie A.
    Kennedy, Sean
    Aslam, Razia
    Carr, Aoife
    Madden, Stephen
    O'Neill, Brian
    Hennessy, Bryan T.
    Toomey, Sinead
    CANCER BIOLOGY & THERAPY, 2023, 24 (01)
  • [6] Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer
    Portman, Neil
    Alexandrou, Sarah
    Carson, Emma
    Wang, Shudong
    Lim, Elgene
    Caldon, C. Elizabeth
    ENDOCRINE-RELATED CANCER, 2019, 26 (01) : R15 - R30
  • [7] Promising Rationally Derived Combination Therapy with PI3K and CDK4/6 Inhibitors
    Muranen, Taru
    Meric-Bernstam, Funda
    Mills, Gordon B.
    CANCER CELL, 2014, 26 (01) : 7 - 9
  • [8] Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer
    Teo, Zhi Ling
    Versaci, Stephanie
    Dushyanthen, Sathana
    Caramia, Franco
    Savas, Peter
    Mintoff, Chris P.
    Zethoven, Magnus
    Virassamy, Balaji
    Luen, Stephen J.
    McArthur, Grant A.
    Phillips, Wayne A.
    Darcy, Phillip K.
    Loi, Sherene
    CANCER RESEARCH, 2017, 77 (22) : 6340 - 6352
  • [9] PI3K mutation is associated with reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer
    Pavithran, K.
    Jayamohanan, H.
    Jose, W. M.
    Soman, S.
    Vijaykumar, D. K.
    Ariyannur, P. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S471 - S471
  • [10] Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?
    Clark, Amy S.
    Makhlin, Igor
    DeMichele, Angela
    CLINICAL CANCER RESEARCH, 2021, 27 (02) : 371 - 373
12345